The World Health Organization (WHO) has released its first analysis of antifungal agents in clinical and preclinical development. The report evaluates the current pipeline, including label extension and repurposed products, and its effectiveness in addressing infections caused by WHO fungal priority pathogens. It also highlights financial and technical limitations in antifungal drug development, particularly in low-resource settings.
Antifungal agents in clinical and preclinical development: overview and analysis
Subscribe to
disAMR Matters
Receive newly released thought leadership articles and news in your inbox twice a month.